Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $43.22 and last traded at $42.64, with a volume of 1115345 shares changing hands. The stock had previously closed at $39.67.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on TARS shares. Oppenheimer restated an “outperform” rating and issued a $63.00 price target (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.60.
Read Our Latest Report on TARS
Tarsus Pharmaceuticals Trading Up 12.9 %
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The business had revenue of $40.81 million during the quarter, compared to the consensus estimate of $31.30 million. During the same quarter in the previous year, the business earned ($1.17) earnings per share. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of institutional investors have recently bought and sold shares of TARS. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares during the period. Dark Forest Capital Management LP acquired a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $202,000. Finally, Bleakley Financial Group LLC bought a new stake in Tarsus Pharmaceuticals during the 1st quarter valued at $223,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
- Five stocks we like better than Tarsus Pharmaceuticals
- Top Stocks Investing in 5G Technology
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Calculate Options Profits
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.